Rodin Therapeutics, Inc.
USPTO PatentsView assignee record - 6 granted patents across 3 technology areas, recorded in grant years 2018–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Rodin ranks #42,716 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 3 technology areas.
- #42,716
- of 49,997 US assignees by volume
- 4th percentile
- by Innovation Score (17.6/100)
- 8.0
- avg claims per patent
- -50%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R42716 · US Corporation #42,716 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-LOW · CLAIMS-PAR · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 6 grants
- LOWER-Q #42,716/49,997
- PHOTO-FINISH Rochester Medical a…
- CPC-NARROW C07D · 3 areas
- INNOV-LOW 17.6/100
- CLAIMS-PAR 8.0 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -50% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Rodin’s 17.6 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Rodin
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Rodin Therapeutics · this assignee 18
Rodin Therapeutics · this assignee
18 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Rodin's Innovation Score is 17.6/100 (4th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Rodin?
Each dot is one of Rodin’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Rodin’s own 8.0 claims/patent is at or below the 14.2 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.
Where Rodin's grants concentrate
Rodin Therapeutics, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). By volume, Rodin sits between Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. and Rollease Acmeda, Inc..
Who files at Rodin's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Rochester Medical…
Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc.
6 patents
- Rochester Sensors
Rochester Sensors, LLC
6 patents
- Rockwell Collins…
Rockwell Collins France S.A.S.
6 patents
- Rodnick
RodNick LLC
6 patents
- Rofin-sinar Laser
Rofin-Sinar Laser GmbH
6 patents
- Rohm Powervation
Rohm Powervation Limited
6 patents
- Rokko Systems Pte
Rokko Systems Pte Ltd
6 patents
- Rollease Acmeda
Rollease Acmeda, Inc.
6 patents
- Rodin Therapeutics ◀
Rodin Therapeutics, Inc.
6 patents
What this shows Rodin holds 6 patents at rank #42,705, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Rodin
By rank, the assignees closest to #42,705 in granted patent volume.
- Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. #42,701 · 6 patents
- Rochester Sensors, LLC #42,702 · 6 patents
- Rockwell Collins France S.A.S. #42,703 · 6 patents
- RodNick LLC #42,704 · 6 patents
- Rofin-Sinar Laser GmbH #42,706 · 6 patents
- Rohm Powervation Limited #42,707 · 6 patents
- Rokko Systems Pte Ltd #42,708 · 6 patents
- Rollease Acmeda, Inc. #42,709 · 6 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in Rodin's primary technology class.
Rodin's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
18 4th percentile higher than 4% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 2 | 33.3% |
| 2019 | 2 | 33.3% |
| 2020 | 2 | 33.3% |
Which technologies does Rodin Therapeutics, Inc. patent most?
Top 3 of 3 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Rodin Therapeutics, Inc.'s patent record in context - here's where to go next.
- Rodin Therapeutics, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #42,716 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Rodin Therapeutics, Inc. against Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc., an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 17.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.